You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 10,562,974

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,562,974

Title:	Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
Abstract:	A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.
Inventor(s):	Ambati; Jayakrishna (Lexington, KY), De Falco; Sandro (Naples, IT)
Assignee:	University of Kentucky Research Foundation (Lexington, KY)
Application Number:	14/772,243
Patent Claims:	1. A method of suppressing angiogenesis, comprising: intravitreously administering to a subject in need of treatment for a condition associated with angiogenesis an isolated Fc fragment of an IgG1 antibody, wherein the administered Fc fragment decreases new blood vessel formation. 2. The method of claim 1, and further comprising administering a drug selected from the group consisting of: bevacizumab, ranibizumab, trastuzumab, sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), everolimus (Afinitor). 3. The method of claim 1, wherein the antibody is monoclonal. 4. The method of claim 1, wherein the antibody is humanized. 5. The method of claim 1, further comprising administering an additional therapeutic agent. 6. The method of claim 5, wherein the additional therapeutic agent is an angiogenesis-inhibiting compound. 7. The method of claim 5, wherein the additional therapeutic agent is an anticancer compound. 8. The method of claim 1, wherein the subject is a human. 9. The method of claim 1, wherein the IgG1 antibody is not selected from the group consisting of bevacizumab, trastuzumab, ado-trastuzumab emtansine, adalimumab, golimumab, efalizumab, canakinumab, pertuzumab, and intravenous immunoglobulin; or is selected from the group consisting of tocilizumab, atilizumab, ofatumumab, alemtuzumab, palivizumab, motavizumab, raxibacumab, belimumab, omalizumab, ipilmumab, daclizumab, ustekinumab, alefacept, elotuzumab, ACE-011, ACE-031, MGAWN1, NCT01736683, MNRP1685A, IMC-A12, IMC 1121B, FG-3019, MT203, necitumumab, immunex, hLL1, IMGN388, AMG 479, AIN457, CD4-IgG, J695, BIIB023, AIN457, IMC-1121B, MEDI4893, nimotuzumab, mepolizumab, TRC105, solanezumab, and ficlatuzumab.

Details for Patent 10,562,974

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997	⤷ Get Started Free	2034-03-13
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	June 19, 1998	⤷ Get Started Free	2034-03-13
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	July 23, 2004	⤷ Get Started Free	2034-03-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	⤷ Get Started Free	2034-03-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	⤷ Get Started Free	2034-03-13
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Get Started Free	2034-03-13
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Get Started Free	2034-03-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.